Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05763082 · ClinicalTrials.gov registry record · Phase 3
Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis
A Phase 3 study, sponsored by Padagis.
- Completed
- Registry status
- Phase 3
- Development phase
- 414
- Enrollment target
NCT05763082 is a Phase 3 study that has completed, run by Padagis. The registered enrollment target is 414 participants.
The verdict
NCT05763082, a Phase 3 study, has completed, sponsored by Padagis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 414 participants
- Enrollment target
Study Summary
To compare the safety and efficacy of Padagis' product to an FDA approved product for the treatment of plaque psoriasis
Interventions
- DRUG Placebo
- DRUG roflumilast cream 0.3%
- DRUG Zoryve
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 414 participants |
| Start Date | 2023-02-07 |
| Est. Completion | 2023-08-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05763082
The ClinicalTrials.gov registry entry for NCT05763082 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 414 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Padagis, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05763082 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05763082 about?
NCT05763082 is a clinical study titled "Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis". To compare the safety and efficacy of Padagis' product to an FDA approved product for the treatment of plaque psoriasis
What is the current status of trial NCT05763082?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 414 participants. The study started on 2023-02-07. Estimated completion is 2023-08-08.
What interventions are being tested in trial NCT05763082?
The interventions under investigation include: Placebo (DRUG), roflumilast cream 0.3% (DRUG), Zoryve (DRUG).
Who is sponsoring clinical trial NCT05763082?
This trial is sponsored by Padagis, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.